NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding NRX Pharmaceuticals, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 25 | 22 | −3 |
| Shares | 1.05M | 2.26M | +1.21M (+115.6%) |
| Value | $2.31M | $4.60M | +$2.30M (+99.5%) |
New holders (4)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 89,086 | $182.6K | 0.00% |
| Two Sigma Investments, LP | 30,146 | $61.8K | 0.00% |
| Northern Trust Corp | 28,601 | $58.6K | 0.00% |
| SBI Securities Co., Ltd. | 2,000 | $4.10K | 0.00% |
Sold out (7)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Susquehanna International Group, LLP | 82,152 | $180.7K |
| Millennium Management LLC | 27,624 | $60.8K |
| Squarepoint Ops LLC | 25,299 | $55.7K |
| Sassicaia Capital Advisers LLC | 15,000 | $33.0K |
| Citigroup Inc | 593 | $1.30K |
| Group One Trading, L.P. | 99 | $218 |
| GWM Advisors LLC | 83 | $183 |